Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 7/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 7/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19110727 | 1.00 | ENPP2 (0.51) | ENPP2KCNK3PTGDR2TAS2R14SIGMAR1 | |
| SCHEMBL19110716 | 0.95 | ENPP2 (0.46) | ENPP2KCNK3PTGDR2SIGMAR1 | |
| SCHEMBL19110701 | 0.93 | ENPP2 (0.50) | ENPP2KCNK3PTGDR2SIGMAR1 | |
| SCHEMBL19110713 | 0.93 | ENPP2 (0.47) | ENPP2KCNK3PTGDR2TAS2R14 | |
| SCHEMBL19110672 | 0.93 | ENPP2 (0.47) | ENPP2KCNK3PTGDR2TAS2R14 | |
| SCHEMBL19110700 | 0.93 | ENPP2 (0.50) | ENPP2KCNK3PTGDR2SIGMAR1 | |
| SCHEMBL19110878 | 0.92 | ENPP2 (0.46) | ENPP2KCNK3PTGDR2SIGMAR1 | |
| SCHEMBL19110879 | 0.92 | ENPP2 (0.46) | ENPP2KCNK3PTGDR2SIGMAR1 | |
| SCHEMBL19110719 | 0.92 | ENPP2 (0.46) | ENPP2KCNK3PTGDR2SIGMAR1 | |
| SCHEMBL19110730 | 0.92 | ENPP2 (0.50) | ENPP2KCNK3PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | ENPP2 1/4885KCNK3 1825/4885PTGDR2 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.